Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/6/2022 | $16.00 → $11.00 | Overweight → Neutral | Cantor Fitzgerald |
6/23/2022 | $40.00 | Buy | Berenberg |
2/2/2022 | $39.00 → $42.00 | Buy | HC Wainwright & Co. |
9/23/2021 | $35.00 | Buy | BTIG Research |
6/28/2021 | $25.00 → $39.00 | Buy | HC Wainwright & Co. |
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. "We are excited about the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing and our team remains de
NEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its fiscal year ended September 30, 2024, on Monday, December 23, 2024. Management will host a conference call on Monday, December 23, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strat
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended June 30, 2024. "We continue to meaningfully advance our differentiated precision medicine clinical program, highlighted by the recent presentation of comprehensive result
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
Blarcamesine potential novel oral treatment to target upstream Alzheimer's disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and therefore anticipates the neurodegenerative process in Alzheimer's disease NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that The Journa
Topline ATTENTION-AD trial: Patients showed improved cognition and function over three years Delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of early treatment initiation Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) di
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th 2025, at the Westin St. Francis in San Francisco, CA. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 09:00 AM – 09:40 AM
10-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced the addition and appointment of new senior team members with a track record of successfully bringing drugs to market. Reinforcing the Company's commitment to drive value-creation through operational efficiencies and innovation in the industry, Anavex announces n
LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. Anavex is engaged in the research, production, and marketing of p
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 18, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing c
Cantor Fitzgerald downgraded Anavex from Overweight to Neutral and set a new price target of $11.00 from $16.00 previously
Berenberg initiated coverage of Anavex with a rating of Buy and set a new price target of $40.00
HC Wainwright & Co. reiterated coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $42.00 from $39.00 previously